India Cell and Gene Therapy CDMO Market Analysis, 2024–2034

The India Cell and Gene Therapy CDMO Market Analysis Executive Summary

Cell and gene therapy CDMOs are contract companies that develop and manufacture cell and gene therapies for biotech and pharma firms.

Key segments of the cell and Gene Therapy CDMO market include service (Process Development, Clinical Manufacturing and Commercial Manufacturing) and product (Viral Vectors, Cell Therapies and Plasmid DNA).

India Cell and Gene Therapy CDMO Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the cell and Gene Therapy CDMO market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the cell and Gene Therapy CDMO market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the cell and Gene Therapy CDMO market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Cell and Gene Therapy CDMO Market in India

The cell and Gene Therapy CDMO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

• LLonza
• Catalent
• Charles River Laboratories
• WWuXi AppTec
• AAGC Biologics
• SSamsung Biologics

Healthcare Policies and Regulatory Landscape for Cell and Gene Therapy CDMO Market in India

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cell and Gene Therapy CDMO. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.

1. 1 Market Analysis

   • 1.1 Research Scope and Assumption
   • 1.2 Objective of the study
   • 1.3 Research Methodology
   • 1.4 Reason to buy the report

2. 2 Market Analysis Executive Summary

   • 2.1 Market Analysis - Industry Snapshot & key buying criteria, 2025-2034
   • 2.2 Market Size, Growth Prospects and Key findings

3. 3 Market Dynamics

   • 3.1 Market Growth Drivers Analysis
   • 3.2 Market Restraints Analysis

4. 4 Market Segmentation

   • 4.1 By Service
   • 4.2 By Product
   • 4.3 By End User

5. 5 By Market Share

   • 5.1 Market Analysis, Insights and Forecast – By Revenue

6. 6 Competitive Landscape

   • 6.1 Major Top Market Players Products in Pipeline
   • 6.2 R&D Initiatives
   • 6.3 Notable recent Deals
   • 6.3.1 Strategic Divestments
   • 6.3.2 Mergers & Acquisitions
   • 6.3.3 Partnerships
   • 6.3.4 Joint Ventures

7. 7 Key Company Profiles

   • 7.1 Lonza
   • 7.2 Catalent
   • 7.3 Charles River Laboratories
   • 7.4 WuXi AppTec
   • 7.5 AGC Biologics
   • 7.6 Samsung Biologics

8. 8 Healthcare Policies and Regulatory Landscape

   • 8.1 Policy changes and Reimbursement scenario
   • 8.2 Government Initiatives / Intervention programs

The cell and Gene Therapy CDMO market can be segmented based on various criteria, including service, product and end user. Here's a breakdown of the market segmentation